NCT01953926Phase 2Terminated

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Study sponsor: Puma Biotechnology, Inc. · PBYI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-01-02Actual
Enrollment · participants582Actual
Source updated2024-03-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview